BackgroundSince December 2019,
Severe acute respiratory syndrome coronavirus 2(
SARS-CoV-2)-infected
disease (Coronavirus Disease 2019,COVID-19) emerged in Wuhan,
China,and rapidly spread throughout
China,even throughout the world. We try to describe the epidemiological and clinical characteristics of COVID-19 in non-Wuhan area,and explore its effective
treatment. MethodsRetrospective, single-center case series of the 51 hospitalized
patients with confirmed COVID-19 at Chongqing
University Three Gorges
Hospital in Chongqing,
China, from January 20 to February 3, 2020;The discharge
time was from January 29 to February 11, 2020. The main results and
indicators of
epidemiology,
demography, clinical manifestation,
laboratory examination, imaging data and
treatment data of 51
patients with covid-19 were collected and analyzed. The changes of
blood routine and biochemical indexes at discharge and admission were compared. Compare the clinical characteristics of severe
patients (including severe and critical
patients) and non-severe
patients (general
patients). ResultsOf 51 hospitalized
patients with COVID-19, the median age was 45 years (interquartile range, 34-51; range, 16-68 years) and 32 (62.7%) were
men.43(84.3%)
patients had been to Wuhan or Other Hubei areas outside Wuhan,and 4(7.7%)
patients had a clear contact
history of COVID-19
patients before the onset of the
disease, and 4 (7.7%)
patients had no clear epidemiological
history of COVID-19.Common symptoms included
fever (43 [84.3%]),
cough (38 [74.5%]) and
fatigue (22 [43.1%]).
Lymphopenia was observed in 26
patients (51.0%), and elevated
C-reactive protein level in 32
patients (62.7%). Ground-
glass opacity was the typical radiological finding on
chest computed
tomography (41 [80.4%]),Local consolidation of
pneumonia in some
patients(17 [33.3%]).Most of the
patients were treated with
traditional Chinese medicine decoction (28 [54.9%]),all of them received
aerosol inhalation of recombinant
human interferon a-1b for
injection and oral
antiviral therapy with
Lopinavir and
Ritonavir tablets (51 [100%]); Most of the
patients were given
Bacillus licheniformis capsules regulated
intestinal flora treatment (44 [86.3%]). 10
patients (19.6%) received short-term (3-5 days)
glucocorticoid treatment. Compared with non-severe
patients (n = 44), severe
patients (n = 7) were older (median age, 52 years vs 44 years), had a higher proportion of
diabetes mellitus (4 [57.1%] vs 0 [0.0%]), most of them needed
antibiotic treatment (7 [100%] vs 4 [9.1%], most of them needed nutritional
diet (6 [85.7%) vs 0 [0.0%], and were more likely to have
dyspnea (6 [85.7%] vs 5 [11.4%]),most of them needed noninvasive
mechanical ventilation (6 [85.7%] vs 0 [0.0%]). Except one
patient died, the remaining 50
patients were discharged according to the discharge standard, the common clinical symptoms disappeared basically, the
lymphocyte increased significantly (P=0.008), CRP decreased significantly (P <0.001). The median
length of stay was 12 days (IQR, 9-13). ConclusionIn 51 single center cases confirmed as COVID-19 and discharged from the
hospital, 13.7% of the
patients were severe. The main clinical symptoms of
patients with COVID-19 were
fever,
cough and
asthenia,Some
patients had obvious
dyspnea. They had clinical
laboratory and radiologic characteristics. There is no specific
drug treatment for the
disease. For the
treatment of COVID-19, in addition to
oxygen inhalation and
antiviral treatment,
attention should be paid to the dialectical
treatment of
traditional Chinese medicine,
regulation of
intestinal flora,
nutritional support treatment and other comprehensive
treatment.